Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)
- Conditions
- Interventions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT00486720
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 94
- Registration Number
- NCT00481078
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
- Conditions
- Interventions
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2015-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 71
- Registration Number
- NCT00479232
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 253
- Registration Number
- NCT00473889
Vorinostat and Palliative Radiotherapy
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT00455351
- Locations
- 🇳🇴
The Norwegian Radium Hospital, Oslo, Norway
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
- Conditions
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 61
- Registration Number
- NCT00423449
Clinical Trial of SAHA in Patients With Breast Cancer
- First Posted Date
- 2006-12-27
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 49
- Registration Number
- NCT00416130
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇸🇬National Cancer Centre, Singapore, Singapore
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
- Conditions
- Acute Erythroid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRefractory AnemiaMyelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Ring SideroblastsAcute Megakaryoblastic LeukemiaMyelodysplastic Syndrome With Excess Blasts
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 135
- Registration Number
- NCT00392353
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT00373490
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2015-11-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT00368875
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.